199 related articles for article (PubMed ID: 30137088)
1. Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage.
Pitek AS; Park J; Wang Y; Gao H; Hu H; Simon DI; Steinmetz NF
Nanoscale; 2018 Sep; 10(35):16547-16555. PubMed ID: 30137088
[TBL] [Abstract][Full Text] [Related]
2. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
3. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
4. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
6. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
7. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
[TBL] [Abstract][Full Text] [Related]
8. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
Absar S; Nahar K; Kwon YM; Ahsan F
Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
[TBL] [Abstract][Full Text] [Related]
9. Extension of the thrombolytic time window with minocycline in experimental stroke.
Murata Y; Rosell A; Scannevin RH; Rhodes KJ; Wang X; Lo EH
Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
[TBL] [Abstract][Full Text] [Related]
10. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
[TBL] [Abstract][Full Text] [Related]
11. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
12. [Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals].
Andreassen AK; Gullestad L; Endresen K
Tidsskr Nor Laegeforen; 1998 Jun; 118(17):2630-1. PubMed ID: 9673511
[TBL] [Abstract][Full Text] [Related]
13. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
[TBL] [Abstract][Full Text] [Related]
14. An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy.
Huang Y; Yu L; Ren J; Gu B; Longstaff C; Hughes AD; Thom SA; Xu XY; Chen R
J Control Release; 2019 Apr; 300():1-12. PubMed ID: 30807804
[TBL] [Abstract][Full Text] [Related]
15. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Roncal C; Martinez de Lizarrondo S; Salicio A; Chevilley A; Rodriguez JA; Rosell A; Couraud PO; Weksler B; Montaner J; Vivien D; Páramo JA; Orbe J
Cardiovasc Res; 2017 Aug; 113(10):1219-1229. PubMed ID: 28379489
[TBL] [Abstract][Full Text] [Related]
16. Protein therapeutics for cardiovascular disease: it is all about delivery.
Ichiki T; Burnett JC
J Am Coll Cardiol; 2012 Dec; 60(24):2558-60. PubMed ID: 23158538
[No Abstract] [Full Text] [Related]
17. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M
Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502
[TBL] [Abstract][Full Text] [Related]
18. Towards safer thrombolytic therapy.
Marder VJ; Stewart D
Semin Hematol; 2002 Jul; 39(3):206-16. PubMed ID: 12124683
[TBL] [Abstract][Full Text] [Related]
19. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
20. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
